|
Adult Myelodysplastic Syndrome
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
GPX3 methylation in bone marrow predicts adverse prognosis and leukemia transformation in myelodysplastic syndrome.
|
27891827 |
2017 |
|
Leukemia, Myelocytic, Acute
|
0.020 |
PosttranslationalModification
|
disease |
BEFREE |
GPX3 methylation was identified in 15% (17/110) MDS patients, and significantly higher than controls, and lower than acute myeloid leukemia (AML) patients (P = 0.024 and 0.041).
|
27891827 |
2017 |
|
MYELODYSPLASTIC SYNDROME
|
0.020 |
PosttranslationalModification
|
group |
BEFREE |
GPX3 methylation density was significantly increased during the progression from MDS to secondary acute myeloid leukemia (sAML) in three follow-up paired patients.
|
27891827 |
2017 |
|
secondary acute myeloid leukemia
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
GPX3 methylation density was significantly increased during the progression from MDS to secondary acute myeloid leukemia (sAML) in three follow-up paired patients.
|
27891827 |
2017 |
|
Malignant neoplasm of colon and/or rectum
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
GPX3 promoter methylation predicts platinum sensitivity in colorectal cancer.
|
27918237 |
2017 |
|
Sudden sensorineural hearing loss
|
0.010 |
Biomarker
|
disease |
BEFREE |
GPX3 may be one of the aetiologies of sudden sensorineural hearing loss (SSNHL), which might be attributed to the genetic effect of GPX3 by influence reactive oxygen species (ROS).
|
28738977 |
2017 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
GPX3 suppresses tumor migration and invasion via the FAK/AKT pathway in esophageal squamous cell carcinoma.
|
30018730 |
2018 |
|
Tumor Cell Invasion
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
GPX3 suppresses tumor migration and invasion via the FAK/AKT pathway in esophageal squamous cell carcinoma.
|
30018730 |
2018 |
|
Malignant neoplasm of lung
|
0.330 |
Biomarker
|
disease |
BEFREE |
GPx3-mediated redox signaling arrests the cell cycle and acts as a tumor suppressor in lung cancer cell lines.
|
30260967 |
2018 |
|
Carcinoma of lung
|
0.030 |
Biomarker
|
disease |
BEFREE |
GPx3-mediated redox signaling arrests the cell cycle and acts as a tumor suppressor in lung cancer cell lines.
|
30260967 |
2018 |
|
Primary malignant neoplasm of lung
|
0.030 |
Biomarker
|
disease |
BEFREE |
GPx3-mediated redox signaling arrests the cell cycle and acts as a tumor suppressor in lung cancer cell lines.
|
30260967 |
2018 |
|
ovarian neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
GPx3 supports ovarian cancer progression by manipulating the extracellular redox environment.
|
30509602 |
2019 |
|
Malignant neoplasm of ovary
|
0.010 |
Biomarker
|
disease |
BEFREE |
GPx3 supports ovarian cancer progression by manipulating the extracellular redox environment.
|
30509602 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.010 |
Biomarker
|
disease |
BEFREE |
GPx3 supports ovarian cancer progression by manipulating the extracellular redox environment.
|
30509602 |
2019 |
|
Neoplasm Metastasis
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
GPx3 is necessary for HGSA ovarian cancer cellular survival in the ascites tumor environment and protects against extracellular sources of oxidative stress, implicating GPx3 as an important adaptation for transcoelomic metastasis.
|
30509602 |
2019 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
GPx3 is an extracellular glutathione peroxidase with reported dichotomous roles in cancer.
|
30509602 |
2019 |
|
Primary malignant neoplasm
|
0.080 |
Biomarker
|
group |
BEFREE |
GPx3 is an extracellular glutathione peroxidase with reported dichotomous roles in cancer.
|
30509602 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
GPX3 mRNA is significantly higher expressed in AT from individuals with normal glucose metabolism compared to T2D patients.
|
30537708 |
2018 |
|
Tumor Cell Invasion
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
GPX3 was hypermethylated in GC (p = 4E-4), and was specific for patients with lymphatic metastasis (+), tumor invasion depth >3 cm and patients with poor differentiation.
|
30924352 |
2019 |
|
melanoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
GPX3 reduced ROS level in MM to inhibit HIF1-α and HIF2-α.
|
31310363 |
2019 |
|
Malignant neoplasm of lung
|
0.330 |
Biomarker
|
disease |
CTD_human |
A 2-DE MALDI-TOF study to identify disease regulated serum proteins in lung cancer of c-myc transgenic mice.
|
19180532 |
2009 |
|
Lung Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
A 2-DE MALDI-TOF study to identify disease regulated serum proteins in lung cancer of c-myc transgenic mice.
|
19180532 |
2009 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
A comparison of GPX3 expression pattern shows a broader down-regulated pattern in multiple types of cancers, including cervical, thyroid, head and neck, lung cancers and melanoma than in healthy controls.
|
20043075 |
2010 |
|
melanoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
A comparison of GPX3 expression pattern shows a broader down-regulated pattern in multiple types of cancers, including cervical, thyroid, head and neck, lung cancers and melanoma than in healthy controls.
|
20043075 |
2010 |
|
Polycystic Ovary Syndrome
|
0.020 |
Biomarker
|
disease |
BEFREE |
A lower concentration of GPx3 was observed in women with PCOS (before the dietetic intervention began) compared with the GPx3 levels in healthy women.
|
30999628 |
2019 |